Spots Global Cancer Trial Database for A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Official Title: A Phase 2 Open-Label Study of the Efficacy of Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Study ID: NCT02966756
Interventions
Study Description
Brief Summary: This is a Phase 2, open-label, multicenter study, evaluating the efficacy of venetoclax in participants with relapsed or refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) either in presence of 17p deletion (Cohort 1) or those who have failed a B-receptor signaling pathway inhibitor (BCRI) therapy and who have also failed, or were unable to receive chemoimmunotherapy (CIT) irrespective of 17p status (Cohort 2).
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Concord Repatriation General Hospital /ID# 201261, Concord, New South Wales, Australia
St George Hospital /ID# 206484, Kogarah, New South Wales, Australia
Monash Medical Centre /ID# 201263, Clayton, Victoria, Australia
Anhui Provincial Cancer Hospital /ID# 209458, Hefei, Anhui, China
Peking University People's Hospital /ID# 156575, Beijing, Beijing, China
Peking Union Medical College Hospital /ID# 156576, Beijing, Beijing, China
Fujian Medical University Union Hospital /ID# 156579, Fuzhou, Fujian, China
Guangdong Provincial People's Hospital /ID# 160509, Guangzhou, Guangdong, China
Nanfang Hospital of Southern Medical University /ID# 156571, Guangzhou, Guangdong, China
The Second Hospital of Hebei Medical University /ID# 159143, Shijiazhuang, Hebei, China
Henan Cancer Hospital /ID# 156573, Zhengzhou, Henan, China
Tongji Hospital Tongji Medical College of HUST /ID# 156589, Wuhan, Hubei, China
Xiangya Hospital Central South University /ID# 208913, Changsha, Hunan, China
Jiangsu Province Hospital /ID# 156577, Nanjing, Jiangsu, China
The First Affiliated Hospital of Soochow University /ID# 156536, Suzhou, Jiangsu, China
The First Affiliated Hospital of Nanchang University /ID# 159142, Nanchang, Jiangxi, China
The First Hospital of Jilin University /ID# 156532, Changchun, Jilin, China
Shandong Provincial Hospital /ID# 156574, Jinan, Shandong, China
Ruijin Hospital, Shanghai Jiaotong University School of Medicine /ID# 156572, Shanghai, Shanghai, China
West China Hospital, Sichuan University /ID# 156537, Chengdu, Sichuan, China
The General Hospital of Western Theater Command PLA /ID# 159145, Chengdu, Sichuan, China
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sc /ID# 157762, Tianjin, Tianjin, China
Tianjin Medical University Cancer Institute & Hospital /ID# 156542, Tianjin, Tianjin, China
The First Affiliated Hospital, Zhejiang University School of Medicine /ID# 156578, Hangzhou, Zhejiang, China
North Shore Hospital /ID# 204637, Takapuna, Auckland, New Zealand
Christchurch Hospital /ID# 201650, Christchurch, Canterbury, New Zealand
Changhua Christian Hospital /ID# 202768, Changhua City, Changhua County, , Taiwan
Kaohsiung Medical University Chung-Ho Memorial Hospital /ID# 202765, Kaohsiung, , Taiwan
China Medical University Hospital /ID# 202767, Taichung, , Taiwan
National Taiwan University Hospital /ID# 210733, Taipei City, , Taiwan
Linkou Chang Gung Memorial Hospital /ID# 203636, Taoyuan City, , Taiwan
Contact Details
Name: ABBVIE INC.
Affiliation: AbbVie
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
